Elevated tumor markers for monitoring tumor response to immunotherapy.

Yang, Yi; Jiang, Xiaolin; Liu, Yun; Huang, Huan; Xiong, Yanli; Xiao, He; Gong, Kan; Li, Xuemei; Kuang, Xunjie; Yang, Xueqin

Yang, Yi; Jiang, Xiaolin; Liu, Yun; Huang, Huan; Xiong, Yanli; Xiao, He; Gong, Kan; Li, Xuemei; Kuang, Xunjie; Yang, Xueqin.

Affiliation

Yang Y; Cancer Department, Daping Hospital, Army Medical University, No. 10 Changjiang Zhi Road, Daping Yuzhong District, Chongqing 400042, China.
Jiang X; Cancer Department, Daping Hospital, Army Medical University, No. 10 Changjiang Zhi Road, Daping Yuzhong District, Chongqing 400042, China.
Liu Y; Cancer Department, Daping Hospital, Army Medical University, No. 10 Changjiang Zhi Road, Daping Yuzhong District, Chongqing 400042, China.
Huang H; Cancer Department, Daping Hospital, Army Medical University, No. 10 Changjiang Zhi Road, Daping Yuzhong District, Chongqing 400042, China.
Xiong Y; Cancer Department, Daping Hospital, Army Medical University, No. 10 Changjiang Zhi Road, Daping Yuzhong District, Chongqing 400042, China.
Xiao H; Cancer Department, Daping Hospital, Army Medical University, No. 10 Changjiang Zhi Road, Daping Yuzhong District, Chongqing 400042, China.
Gong K; Cancer Department, Daping Hospital, Army Medical University, No. 10 Changjiang Zhi Road, Daping Yuzhong District, Chongqing 400042, China.
Li X; Cancer Department, Daping Hospital, Army Medical University, No. 10 Changjiang Zhi Road, Daping Yuzhong District, Chongqing 400042, China.
Kuang X; Cancer Department, Daping Hospital, Army Medical University, No. 10 Changjiang Zhi Road, Daping Yuzhong District, Chongqing 400042, China.
Yang X; Cancer Department, Daping Hospital, Army Medical University, No. 10 Changjiang Zhi Road, Daping Yuzhong District, Chongqing 400042, China.

EClinicalMedicine ; 46: 101381, 2022 Apr.

Article in En | MEDLINE | ID: mdl-35434583

Key words

CR, Complete response; Efficacy evaluation; ICIs, Immune checkpoint inhibitors; Immunotherapy; NE, Not estimated; NSCLC, Non-small cell lung cancer; ORR, Objective response rate; OS, Overall survival; PD, Progressive disease; PR, Partial response; RECIST; RECIST, Response Evaluation Criteria in Solid Tumors; RecistTM, Response evaluation criteria in solid tumors based on tumor markers; SD, Stable disease; Tumor markers; irCR, Immune-related complete response; irPD, Immune-related progression disease; irPR, Immune-related partial response; irRECIST, Immune-related Response Evaluation Criteria in Solid Tumors; irSD, Immune-related stable disease; tmCR, Tumor marker-related complete response; tmPD, Tumor marker-related progression disease; tmPR, Tumor marker-related partial response; tmSD, Tumor marker-related stable disease

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Language: En Journal: EClinicalMedicine Year: 2022 Document type: Article Affiliation country: Country of publication:

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google